研究方向
1.抗病毒广谱中和抗体药物的开发和中和机理研究
2.抗病毒广谱中和抗体的生物治疗应用研究
3.新发突发传染病防治策略研究
重要学术贡献
黄竞荷博士长期从事艾滋病广谱中和抗体及流感疫苗的研究，她开创性地开发了一种直接从B淋巴细胞中分离抗体的新技术 （Nature Protocols 2013）。她从艾滋病病人体内分离到一系列的新型高效广谱中和抗体10E8、35O22和N6。10E8和N6能中和98%HIV-1的强效中和抗体. 10E8结合病毒的位点位于gp41的MPER区域，而N6则针对gp120 CD4的结合位点（Nature 2012和Immunity 2016）。35O22能结合艾滋病病毒新位点的抗体（Nature 2014）。目前，10E8和N6已经在NIAID疫苗研究中心（VRC）进行I期人体临床试验。著名生物制药公司赛诺非 (Sanofi)、葛兰素史克股份有限公司 (GlaxoSmithKline) 和吉利德公司（Gilead Science）正在利用该抗体进行艾滋病治疗药物的开发研究。黄竞荷博士近年来在国际学术期刊上发表SCI论文26篇 （其中第一作者的论文15篇），其重大学术成果发表在Nature (2篇)、Immunity、Nature Protocols、JEM 和 JCI等国际知名杂志。IF>10 分的文章5篇，总影响因子超过300。其研究成果在2013和2014年连续两年被评为美国国立卫生研究院NIAID重大发现之一。多次被国际艾滋病疫苗大会和免疫学大会邀请作口头会议报告。获得2009年艾滋病疫苗会议国际奖学金；2009-2011年连续三年获得逆转录病毒和机会性感染会议青年科学家奖学金；2010年 第18届国际艾滋病会议奖学金；2014-2015年美国国立卫生研究院优秀工作奖。2017年获得国家自然科学基金面上项目一项， “十三五”重大专项“艾滋病功能性治愈策略与临床研究”牵头人。
荣誉与获奖
2015 美国国立卫生研究院 优秀工作奖
2016 美国国立卫生研究院 优秀工作奖
2017 “十三五”重大专项“艾滋病功能性治愈策略与临床研究”牵头人
国内外学术团体任职
2008-今 International AIDS Society
受邀审稿学术刊物
2010-今 PLoS Pathogens，PLoS One (4 manuscripts)，Scientific Reports，Microbes and Infection and FEBS Letter
校内学术机构任职
受邀学术报告
2012 报告题目，会议名称，地点
1.2012 Isolation of a Broad, Potent, MPER-Specific Monoclonal Antibody with Novel Binding Characteristics. Keystone Symposia HIV Vaccines (X5), Colorado March 21-26, 2012
2.2012 HIV-1 cohort: a resource for identifying effective antibodies. Infectious Disease Prevention and Therapy, Philadelphia Nov14-16 2012
3.2014 Live Adenovirus type 4 Recombinants Induce Durable Neutralizing Antibody Responses to Influenza H5 with High Levels of Somatic Hypermutation in Humans. HIVR4P, Cape Town, South Africa, 28-31 October 2014.
4.2015 Isolation of a Broad and Potent CD4-Binding Site Monoclonal Antibody with Novel Binding Characteristics. 2015 Keystone Symposia HIV Vaccines (X5), Banff, Alberta, Canada. March 22-27, 2015
5.2016 Intranasal Replication Competent Adenovirus type 4-Influenza-H5 (Ad4-H5-Vtn) Vaccine Induces Durable Neutralizing Antibody Responses in Humans. 2016 Keystone Symposia HIV Vaccines (X8)，Resort at Squaw Creek - Olympic Valley, California, USA March 22 2016
6.2016 Upper Respiratory Tract (URT) Administration of a Replication Competent Ad4-H5-Vtn Vaccine Induces Durable Neutralizing Antibody Responses in Humans. HIVR4P Chicago, Oct 18 2016
7.2017 N6：能中和98%HIV-1病毒的CD4结合位点抗体 二届全国病毒进入（入侵）及进入抑制剂研讨会 大理， 2017-3-17 (特邀专家报告)
8.2017 艾滋病毒广谱中和抗体 中科院交叉学科论坛. 上海，2017-4-4 (学术报告).
9.2017 艾滋病毒广谱中和抗体的研究 2017年上海市医学会感染病学/病毒学分会联合年会. 上海， 2017-5-20 (学术报告).
10.2017 针对gp120 CD4结合位点的新型广谱中和抗体及其中和机制的研究 2017年艾滋病学术大会，广州，2017-9-27（学术报告）
11.2017 Broadly neutralizing antibodies and their roles on vaccine design. Grand Challenges on HIV Cure and Vaccine, Hong Kong, China 2017-11-30
发表论文
1.Zou P#, Li Y#, Huang J*, Wu F*. Self-assembly polymerization enhances the immunogenicity of influenza M2e peptide. Microbes Infect. 2017 S1286-4579(17)：30148 (共通讯作者)
2.Huang J#, Kang BH#, Ishida E#, Zhou T#, Griesman T, Sheng Z, Wu F, Doria-Rose NA, Zhang B, McKee K, O'Dell S, Chuang GY, Druz A, Georgiev IS, Schramm CA, Zheng A, Joyce MG, Asokan M, Ransier A, Darko S, Migueles SA, Bailer RT, Louder MK, Alam SM, Parks R, Kelsoe G, Von Holle T, Haynes BF, Douek DC, Hirsch V, Seaman MS, Shapiro L, Mascola JR, Kwong PD, Connors M*. A CD4-Binding Site Antibody to HIV that Evolved Extraordinary Neutralization Breadth. Immunity 2016, 45(5):1108-1121
3.Huang J, Kang B, Pancera M, Lee JH, Tong T, Feng Y, Imamichi H, Georgiev I, Chuang GY, Druz A, Doria-Rose NA, Laub L, Sliepen K, van Gils M, de la Peña AT, Derking R, Klasse PJ, Migueles SA, Bailer RT, Alam SM, Pugach P, Haynes BF, Wyatt RT, Sanders RW, Binley JM, Ward AB, Mascola JR, KwongPD, Connors M*. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-120 interface Nature. 2014, 515(7525):138-42
4.Huang J#, Doria-Rose NA#, Longo NS#, Laub L, Lin CL, Turk E, Kang B, Migueles SA, Bailer RT, Mascola JR, Connors M*. Isolation of human monoclonal antibodies from peripheral blood B cells. Nature Protocols. 2013, 8(10):1907-1915
5.Huang J#, Ofek G#, Laub L, Louder MK, Doria-Rose NA, Longo NS, Imamichi H, Bailer RT, Chakrabarti B, Sharma SK, Alam SM, Wang T, Yang Y, Zhang B, Migueles SA, Wyratt R, Haynes BF, KwongPD, Mascola JR, Connors M*. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature. 2012, 491(7424):406-12
6.Huang J#, Al-Mozaini M#, Rogich J, Carrington MF, Seiss K, Pereyra F, Lichterfeld M, Yu XG*. Systemic inhibition of myeloid dendritic cells by circulating HLA class I molecules in HIV-1 infection. Retrovirology. 2012, 9:11
7.Huang J#, Yang Y#, Al-mozaini M, Burke PS, Beamon J, Carrington M, Seiss K, Rychert J, Rosenberg E, Lichterfeld M, Yu XG*. Dendritic cell dysfunction during primary HIV-1 infection. Journal of Infectious Disease. 2011, 204(10):1557-62
8.Chen H#, Li C#, Huang J#, Cung T#, Seiss K, Beamon J, Carrington MF, Porter LC, Burke PS, Yang Y, Ryan BJ, Liu R, Weiss RH, Pereyra F, Cress WD, Brass AL, Rosenberg ES, Walker BD, Yu XG, Lichterfeld M. CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. The Journal of Clinical Investigation. 2011, 121(4):1549-60
9.Yang Y#, Huang J#, Toth I, Lichterfeld M, Yu XG*. Mutational escape in HIV-1 CTL epitopes leads to increased binding to inhibitory myelomonocytic MHC class I receptors. PLoS One. 2010, 5(12):e15084
10.Huang J, Burke P, Yang Y, Seiss K, Beamon J, Cung T, Toth I, Pereyra F, Lichterfeld M, Yu XG*. Soluble HLA-G inhibits myeloid dendritic cell function in HIV-1 infection by interacting with leukocyte immunoglobulin-like receptor B2. Journal of Virology. 2010, 84(20):10784-91
11.Huang J, Burke P, Cung TD, Pereyra F, Toth I, Walker BD, Borges L, Lichterfeld M, Yu XG*. Leukocyte Immunoglobulin-like Receptors maintain unique antigen-presenting properties of circulating myeloid dendritic cells in HIV-1 elite controllers. Journal of Virology. 2010, 84(18):9463-71
12.Huang J, Goedert J, Sundberg E, Cung T, Burke P, Martin P, Lifson J, Lichterfeld M, Carrington M, Yu XG*. HLA-B*35-Px-mediated acceleration of HIV-1 infection by increased inhibitory immunoregulatory impulses. The Journal of Experimental Medicine. 2009, 206(13):2959-2966
13.Huang JH, Qi Z, Wu F, Kotula L, Jiang S*, Chen YH*. Interaction of HIV-1 gp41 core with NPF motif in Epsin: implication in endocytosis of HIV. The Journal of Biological Chemistry. 2008, 283(22):14994-5002
14.Huang JH, Lu L, Lu H, Chen X, Jiang S*, Chen YH*. Identification of the HIV-1 gp41 core-binding motif in the scaffolding domain of caveolin-1. The Journal of Biological Chemistry. 2007, 282(9):6143-6152
15.Huang JH, Yang HW, Liu S, Li J, Jiang S*, Chen YH*. The mechanism by which molecules containing the HIV-1 gp41 core-binding motif HXXNPF inhibit HIV-1 envelope glycoprotein-mediated syncytium-formation. Biochemical Journal. 2007, 403(3):565-571
16.Huang JH, Liu ZQ, Liu S, Jiang S*, Chen YH*. Identification of the HIV-1 gp41 core-binding motif--HXXNPF. FEBS Letter. 2006, 580(20):4807-4814
学术专著
申请或授权专利
授权专利
1.Neutralizing gp41 antibodies and their use. Patent number: WO2013070776
2.Neutralizing antibodies to HIV-1 env and their use. WO2015103549A1
3.Neutralizing antibodies to gp120 and their use. WO2016154003A8
发表于 2019-5-6 15:26:11
QQ好友和群
QQ空间
腾讯微博
腾讯朋友
收藏
分享
支持
反对
楼主
